RedHill Biopharma (RDHL) Further Analysis of Phase 2/3 Data Shows 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 Patients

Go back to RedHill Biopharma (RDHL) Further Analysis of Phase 2/3 Data Shows 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 Patients

RedHill Biopharma (RDHL) Announces Talicia added to Medi-Cal Contract Drug List with No Prior Authorization Requirements

October 6, 2021 7:01 AM EDT

RedHill Biopharma Ltd. (Nasdaq: RDHL), a specialty biopharmaceutical company, today announced that Medi-Cal - California's Medicaid Health Care program covering two million patients - has added Talicia® (omeprazole magnesium, amoxicillin and rifabutin)[1] to its Contract Drug List (CDL) for H. pylori treatment, with no prior authorization required, effective October 1,... More

RedHill Biopharma (RDHL) Reports Further Analysis of Phase 2/3 Data Including a 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 Patients

October 4, 2021 8:15 AM EDT

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported new data from the opaganib global Phase 2/3 study in hospitalized patients with severe COVID-19 pneumonia showing that treatment with oral opaganib (ABC294640)[1] vs. the placebo-controlled arm resulted in a 62% statistically significant reduction in mortality as well as statistically significant improved outcomes in time to room air and median time to hospital discharge in a group of 251 hospitalized, moderately severe COVID-19 patients, comprising 53% of the... More